AtriCure Bipolar Radiofrequency Ablation of Persistent Atrial Fibrillation
ABLATE Persistent is a prospective, non-randomized multi-center clinical trial to demonstrate the safety and effectiveness of the AtriCure Bipolar System for treating persistent atrial fibrillation during concomitant on-pump cardiac surgery.
- The primary efficacy endpoint for this study is the percent of patients free from AF and off Class I and III antiarrhythmic drugs at 9 months.
- The primary safety endpoint is the composite acute major adverse event rate, within 30 days post-procedure or hospital discharge
- The secondary efficacy endpoint for this study is the percent of patients free from AF, independent of antiarrhythmic drug status at 9 months
- The secondary safety endpoint is the composite 9-month post-procedure major adverse event rate.
No Contacts or Locations Provided